Press Releases

AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Safety data updates for Phase 1 and 2 Fabry disease clinical trials and Phase 1/2 Gaucher disease type 1 clinical trial show no adverse events or serious adverse events related to drug product CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- AVROBIO, Inc.

Nov 24, 2021

AVROBIO to Present at Two Upcoming Investor Conferences in November

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming

Nov 09, 2021

AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher

Nov 08, 2021

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to

Nov 05, 2021

AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update

Provided comprehensive safety update on AVROBIO’s lentiviral gene therapy platform and programs at ESGCT 2021 Received FDA feedback on CMC requirements for anticipated Fabry disease registration trial; registration study initiation anticipated for mid-2022 Cash runway extended into fourth quarter

Nov 04, 2021

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 3, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease

Nov 03, 2021

AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 26, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today announced the appointment of Essra Ridha , M.D., MRCP, FFPM, as chief medical officer. Dr.

Oct 26, 2021

AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 20, 2021-- AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will present at the Jefferies Virtual Gene

Oct 20, 2021

AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1

No adverse events or serious adverse events related to drug product in 14 patients treated in Phase 1 and 2 Fabry disease trials and Phase 1/2 Gaucher disease trial Post-gene therapy administration safety data out 4½ years for first patient dosed AVROBIO leads way with new industry-leading

Oct 19, 2021

AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress

New safety data to be reported from clinical trials in Fabry disease and Gaucher disease type 1 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today

Oct 06, 2021



Displaying 1 - 10 of 35

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.